Secondary diabetes associated with principal endocrinopathies: The impact of new treatment modalities

Acta Diabetologica

Volumn 46, Issue 2, 2009, Pages 85-95

  Resmini, Eugenia ^a   Minuto, Francesco ^a   Colao, Annamaria ^b   Ferone, Diego ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Acromegaly; Cushing's syndrome; Insulin analogues; Neuroendocrine tumours; Secondary diabetes

Indexed keywords

ANTIDIABETIC AGENT; FATTY ACID; GLUCOCORTICOID; GLUCOSE; GROWTH HORMONE; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SULFONYLUREA DERIVATIVE;

ACROMEGALY; ADD ON THERAPY; CARCINOID; CARDIOVASCULAR RISK; CUSHING SYNDROME; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG HALF LIFE; DRUG MECHANISM; DYSLIPIDEMIA; ENDOCRINE DISEASE; FATTY ACID BLOOD LEVEL; GLUCAGONOMA; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPERCOAGULABILITY; HYPERCORTISOLISM; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPERTHYROIDISM; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; KINESIOTHERAPY; LIPOLYSIS; MORBIDITY; MORTALITY; NEUROENDOCRINE TUMOR; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS RESECTION; PANCREAS SURGERY; PATHOGENESIS; PHEOCHROMOCYTOMA; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SKELETAL MUSCLE; SOMATOSTATINOMA; THYROID DISEASE; THYROID MEDULLARY CARCINOMA; WEIGHT GAIN;

ACROMEGALY; CUSHING SYNDROME; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; ENDOCRINE SYSTEM DISEASES; GLUCONEOGENESIS; GLUCOSE TOLERANCE TEST; HUMAN GROWTH HORMONE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIVER; PREVALENCE; RISK FACTORS;

EID: 67349224686     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-009-0112-9     Document Type: Review

References (73)

1. A Ben-Shlomo S Melmed 2001 Acromegaly Endocrinol Metab Clin North Am 30 565 583 (Pubitemid 32852804)
2. M Doga S Bonadonna A Burattin A Giustina 2001 Ectopic secretion of growth hormone-releasing hormone (GHRH) in neuroendocrine tumors: relevant clinical aspects Ann Oncol 12 Suppl 2 S89 S94 (Pubitemid 33069694)
3. F Salehi S Cohen LV Syro H Uribe E Horvath K Kovacs SL Asa 2006 Plurihormonality in pituitary adenomas associated with acromegaly Endocr Pathol 17 291 296 (Pubitemid 46279677)
4. D Ferone R Pivonello S Lastoria A Faggiano ML Del Basso de Caro P Cappabianca G Lombardi A Colao 2001 In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy Clin Endocrinol (Oxf) 54 469 477 (Pubitemid 34204183)
5. L Alexander D Appleton R Hall WM Ross R Wilkinson 1980 Epidemiology of acromegaly in the Newcastle region Clin Endocrinol 12 71 79 (Pubitemid 10174985)
6. BA Bengtsson S Edén I Ernest A Odén B Sjögren 1988 Epidemiology, long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984 Acta Med Scand 223 327 335 (Pubitemid 18169191)
7. IM Holdaway RC Rajasoorya GD Gamble 2004 Factors influencing mortality in acromegaly J Clin Endocrinol Metab 89 667 674 (Pubitemid 38269875)
8. J Ayuk RN Clayton G Holder MC Sheppard PM Stewart AS Bates 2004 Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly J Clin Endocrinol Metab 89 1613 1617 (Pubitemid 38507910)
9. IM Holdaway 2007 Excess mortality in acromegaly Horm Res 68 Suppl 5 166 172
10. A Colao D Ferone P Marzullo G Lombardi 2004 Systemic complications of acromegaly: epidemiology, pathogenesis, and management Endocr Rev 25 102 152 (Pubitemid 38269977)
11. JDN Nabarro 1987 Acromegaly Clin Endocrinol (Oxf) 26 481 512 (Pubitemid 17036415)
12. H Biering G Knappe H Gerl H Lochs 2000 Prevalence of diabetes in acromegaly and Cushing syndrome Acta Med Austriaca 27 27 31
13. A Kreze E Kreze-Spirova M Mikulecky 2001 Risk factors for glucose intolerance in active acromegaly Braz J Med Biol Res 34 1429 1433 (Pubitemid 34036845)
14. S Suzuki 1996 Diabetes secondary to endocrinolopathies Nippon Rinsho 54 2709 2714
15. YL Chen CP Wei CC Lee TC Chang 2007 Diabetic ketoacidosis in a patient with acromegaly J Formos Med Assoc 106 788 791
16. HA Tran N Petrovsky AJ Field 2002 Severe diabetic retinopathy: a rare complication of acromegaly Intern Med J 32 52 54 (Pubitemid 36124640)
17. A Colao R Baldelli P Marzullo E Ferretti D Ferone P Gargiulo M Petretta G Tamburrano G Lombardi A Liuzzi 2000 Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy J Clin Endocrinol Metab 85 193 199 (Pubitemid 32268813)
18. B Larijani M Nakhjavani R Baradar-Jalili SM Akrami F Bandarian 2005 Diabetes mellitus following pituitary adenomectomy in euglycaemic patients with acromegaly J Coll Physicians Surg Pak 15 430 432 (Pubitemid 41131449)
19. R Baldelli C Battista F Leonetti MR Ghiggi MC Ribaudo A Paoloni E D'Amico E Ferretti R Baratta A Liuzzi V Trischitta G Tamburrano 2003 Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogueues treatment Clin Endocrinol (Oxf) 59 492 499 (Pubitemid 37188181)
20. BL Koop AG Harris S Ezzat 1994 Effect of octreotide on glucose tolerance in acromegaly Eur J Endocrinol 130 581 586 (Pubitemid 24203412)
21. CL Ronchi V Varca P Beck-Peccoz E Orsi F Donadio A Baccarelli C Giavoli E Ferrante A Lania A Spada M Arosio 2006 Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors J Clin Endocrinol Metab 91 121 128 (Pubitemid 43069127)
22. A Colao RS Auriemma M Galdiero P Cappabianca LM Cavallo F Esposito LF Grasso G Lombardi R Pivonello 2009 Impact of somatostatin analogs vs. surgery on glucose metabolism in acromegaly: results of a 5 years observational, open, prospective study J Clin Endocrinol Metab 94 528 537
23. R Baldelli L De Marinis A Bianchi R Pivonello V Gasco R Auriemma G Pasimeni V Cimino M Appetecchia M Maccario G Lombardi A Pontecorvi A Colao S Grottoli 2008 Microalbuminuria in insulin sensitivity in patients with growth hormone-secreting pituitary tumor J Clin Endocrinol Metab 93 710 714
24. AN Paisley WM Drake 2005 Treatment of pituitary tumors: pegvisomant Endocrine 28 111 114 (Pubitemid 43004808)
25. AL Barkan P Burman DR Clemmons WM Drake RF Gagel PE Harris PJ Trainer AJ van der Lely ML Vance 2005 Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant J Clin Endocrinol Metab 90 5684 5691 (Pubitemid 41415476)
26. R Pivonello MC De Martino M De Leo G Lombardi A Colao 2008 Cushing's syndrome Endocrinol Metab Clin North Am 37 135 149
27. A Faggiano R Pivonello S Spiezia MC De Martino M Filippella C Di Somma G Lombardi A Colao 2003 Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission J Clin Endocrinol Metab 88 2527 2533 (Pubitemid 36724418)
28. M Terzolo B Allasino S Bosio E Brusa F Daffara M Ventura E Aroasio G Sacchetto G Reimondo A Angeli C Camaschella 2004 Hyperhomocysteinemia in patients with Cushing's syndrome J Clin Endocrinol Metab 89 3745 3751 (Pubitemid 39071467)
29. L Tauchmanovà R Rossi B Biondi M Pulcrano V Nuzzo EA Palmieri S Fazio G Lombardi 2002 Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk J Clin Endocrinol Metab 87 4872 4878 (Pubitemid 35316318)
30. JM Connell JA Whitworth DL Davies AF Lever AM Richards R Fraser 1987 Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal functio in normal man J Hypertens 5 425 433 (Pubitemid 17126233)
31. A Colao R Pivonello S Spiezia A Faggiano D Ferone M Filippella P Marzullo G Cerbone M Siciliani G Lombardi 1999 Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure J Clin Endocrinol Metab 84 2664 2672 (Pubitemid 30641990)
32. I Chiodini M Torlontano V Carnevale V Trischitta A Scillitani 2008 Skeletal involvement in adult patients with endogenous hypercortisolism J Endocrinol Invest 31 267 276
33. G Arnaldi T Mancini B Polenta M Boscaro 2004 Cardiovascular risk in Cushing's syndrome Pituitary 7 253 256 (Pubitemid 43115861)
34. B Catargi V Rigalleau A Poussin N Ronci-Chaix V Bex V Vergnot H Gin P Roger A Tabarin 2003 Occult Cushing's syndrome in type-2 diabetes J Clin Endocrinol Metab 88 5808 5813 (Pubitemid 38033055)
35. JE Nestler MA McClanahan 1992 Diabetes and adrenal disease Baillieres Clin Endocrinol Metab 6 829 847
36. MB Urowitz D Gladman D Ibañez P Fortin J Sanchez-Guerrero S Bae A Clarke S Bernatsky C Gordon J Hanly D Wallace D Isenberg E Ginzler J Merrill G Alarcon K Steinsson M Petri MA Dooley I Bruce S Manzi M Khamashta R Ramsey-Goldman A Zoma G Sturfelt O Nived P Maddison J Font R van Vollenhoven C Aranow K Kalunian T Stoll J Buyon 2007 Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort Lupus 16 731 735 (Pubitemid 47517869)
37. C Meier T Kapellen RB Tröbs W Hirsch R Parwaresch W Kiess D Körholz 2006 Temporary diabetes mellitus secondary to a primary pancreatic Burkitt lymphoma Pediatr Blood Cancer 47 94 96 (Pubitemid 43787916)
38. M Steffens V Beauloye B Brichard A Robert O Alexopoulou Vermylen Ch D Maiter 2008 Endocrine and metabolic disorders in young adult survivors of childhood acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL) Clin Endocrinol (Oxf) 69 819 827
39. JR Roberson S Raju J Shelso CH Pui SC Howard 2008 Diabetic ketoacidosis during therapy for pediatric acute lymphoblastic leukemia Pediatr Blood Cancer 50 1207 1212
40. IM Modlin SF Moss DC Chung RT Jensen E Snyderwine 2008 Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors J Natl Cancer Inst 100 1282 1289
41. IM Modlin K Oberg DC Chung RT Jensen WW de Herder RV Thakker M Caplin G Delle Fave GA Kaltsas EP Krenning SF Moss O Nilsson G Rindi R Salazar P Ruszniewski A Sundin 2008 Gastroenteropancreatic neuroendocrine tumours Lancet Oncol 9 61 72
42. Solcia E, Kloppel G, Sobin LH (1999) Histological typing of endocrine tumours. WHO international classification of tumours, 2nd edn. Springer, Berlin, pp 61-67
43. UF Pape H Jann J Müller-Nordhorn A Bockelbrink U Berndt SN Willich M Koch C Röcken G Rindi B Wiedenmann 2008 Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors Cancer 113 256 265
44. C Jiménez MI Hu RF Gagel 2008 Management of medullary thyroid carcinoma Endocrinol Metab Clin North Am 37 481 496
45. I Ilias K Pacak 2008 A clinical overview of pheochromocytomas/ paragangliomas and carcinoid tumors Nucl Med Biol 35 Suppl 1 S27 S34
46. TD Wiesner M Blüher M Windgassen R Paschke 2003 Improvement of insulin sensitivity after adrenalectomy in patients with pheochromocytoma J Clin Endocrinol Metab 88 3632 3636 (Pubitemid 37034506)
47. C Ishii K lnoue K Negishi N Tane T Awata S Katayama 2001 Diabetic ketoacidosis in a case of pheochromocytoma Diabetes Res Clin Pract 54 137 142 (Pubitemid 32964684)
48. VZ Schusdziarra 1999 Glucagonoma-somatostatinoma Gastroenterol Suppl 1 33 35
49. JD Allendorf BA Schrope MH Lauerman WB Inabnet JA Chabot 2007 Postoperative glycaemic control after central pancreatectomy for mid-gland lesions World J Surg 31 164 168 (Pubitemid 46089560)
50. Oberg K, Kaltsas G, Ferone D, Plöckinger U (2008) Standards of care in neuroendocrine tumors: biotherapy. neuroendocrinology. Dec 11 (epub ahead of print)
51. F Monaco 2003 Classification of thyroid diseases: suggestions for a revision J Clin Endocrinol Metab 88 1428 1432
52. W Roubsanthisuk P Watanakejorn M Tunlakit S Sriussadaporn 2006 Hyperthyroidism induces glucose intolerance by lowering both insulin secretion and peripheral insulin sensitivity J Med Assoc Thai 89 Suppl 5 S133 S140 (Pubitemid 46193142)
53. M Mouradian N Abourizk 1983 Diabetes mellitus and thyroid disease Diabetes Care 6 512 520
54. HP Himsworth RB Kerr 1939 Insulin-sensitive and insulin insensitive types of diabetes mellitus Clin Sci 4 119 152
55. DM Nathan JB Buse MB Davidson E Ferrannini RR Holman R Sherwin B Zinman American Diabetes Association European Association for Study of Diabetes 2009 Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 193 203 (Pubitemid 44156663)
56. KS Polonsky BD Given LJ Hirsch H Tillil ET Shapiro C Beebe BH Frank JA Galloway E Van Cauter 1988 Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus N Engl J Med 318 1231 1239 (Pubitemid 18120885)
57. U.K. prospective diabetes study 16 1995 Overview of 6 years' therapy of type II diabetes: a progressive disease Diabetes 44 1249 1258
58. B Glaser E Cerasi 1999 Early intensive insulin treatment for induction of long-term glycaemic control in type 2 diabetes Diabetes Obes Metab 1 67 74
59. JA Mayfield RD White 2004 Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function Am Fam Physician 70 489 500 (Pubitemid 39045561)
60. F Wang JM Carabino CM Vergara 2003 Insulin glargine: a systemic review of a long-acting insulin analogue Clin Ther 25 1541 1577 (Pubitemid 36801936)
61. H Yki-Järvinen L Ryysy K Nikkila T Tulokas R Vanamo M Heikkilä 1999 Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial Ann Intern Med 130 389 396 (Pubitemid 29111220)
62. Skyler JS (1998) Insulin therapy in type 2 diabetes mellitus. In: DeFronzo RA (ed) Current therapy of diabetes mellitus. Mosby, St. Louis, pp 108-116
63. P Gaede P Vedel N Larsen GV Jensen HH Parving O Pedersen 2003 Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 383 393 (Pubitemid 36159355)
64. SM Strowig ML Aviles-Santa P Raskin 2002 Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes Diabetes Care 25 1691 1698 (Pubitemid 41071072)
65. J Rosenstock G Dailey M Massi-Benedetti A Fritsche Z Lin A Salzman 2005 Reduced hypoglycemia risk with insulin glargine A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes Diabetes Care 28 950 955 (Pubitemid 40434505)
66. F Holleman JB Hoekstra 1997 Insulin lispro N Engl J Med 337 176 183 (Pubitemid 27306290)
67. M Lepore S Pampanelli C Fanelli F Porcellati L Bartocci A Di Vincenzo C Cordoni E Costa P Brunetti GB Bolli 2000 Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analogue glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro Diabetes 49 2142 2148
68. S Leichter 2008 Is the use of insulin analogues cost-effective? Adv Ther 25 285 299
69. RH Becker AD Frick L Teichert L Nosek L Heinemann T Heise K Rave 2008 Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects Diabetes Obes Metab 10 1105 1113
70. SA Schreiber T Haak 2007 Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12, 216 patients Diabetes Obes Metab 9 31 38
71. CJ Dunn GL Plosker GM Keating K McKeage LJ Scott 2003 Insulin glargine: an updated review of its use in the management of diabetes mellitus Drugs 63 1743 1778 (Pubitemid 36999964)
72. A Colao G Arnaldi P Beck-Peccoz S Cannavò R Cozzi E degli Uberti L De Marinis E De Menis D Ferone V Gasco A Giustina S Grottoli G Lombardi P Maffei E Martino F Minuto R Pivonello E Ghigo 2007 Pegvisomant in acromegaly: why, when, how J Endocrinol Invest 30 693 699 (Pubitemid 350104101)
73. U Plöckinger T Reuter 2008 Pegvisomant increases intra-abdominal fat in patients with acromegaly: a pilot study Eur J Endocrinol 158 467 471